Advertisement
Screener

Allarity Therapeutics, Inc. (ALLR) Interest Expense

2.8 / 5 stars · 68/120 Roast Me

Allarity Therapeutics, Inc. Interest Expense

Allarity Therapeutics, Inc. (ALLR) reported Interest Expense of $102.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.

Discontinued › Expense Statement › Interest Expense

us-gaap:InterestExpense · last filed 2024-05-14

  • Allarity Therapeutics, Inc. interest expense for the quarter ending 2024-03-31 was $102.00K, a 10.87% increase year-over-year.
  • Allarity Therapeutics, Inc. interest expense for the quarter ending 2023-12-31 was $230.00K, a 98.28% increase year-over-year.
  • Allarity Therapeutics, Inc. interest expense for the quarter ending 2023-09-30 was $34.00K, a 2.86% decline year-over-year.
  • Allarity Therapeutics, Inc. interest expense for the quarter ending 2023-06-30 was $142.00K, a 330.30% increase year-over-year.
  • Allarity Therapeutics, Inc. interest expense for fiscal 2023 was $498.00K, a 123.32% increase from fiscal 2022.
  • Allarity Therapeutics, Inc. interest expense for fiscal 2022 was $223.00K.
  • Allarity Therapeutics, Inc. interest expense for fiscal 2020 was $93.00K.
Period endInterest Expense 3 monthInterest Expense 6 monthInterest Expense 9 monthInterest Expense 12 monthInterest Expense 12 month as first filed
2024-03-31$102.00K
10-Q · filed 2024-05-14
$332.00K
derived: sum of 2 quarters · filed 2024-05-14
$366.00K
derived: sum of 3 quarters · filed 2024-05-14
$508.00K
derived: sum of 4 quarters · filed 2024-05-14
2023-12-31$230.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08
$264.00K
derived: sum of 2 quarters · filed 2024-03-08
$406.00K
derived: sum of 3 quarters · filed 2024-03-08
$498.00K
10-K · filed 2024-03-08
2023-09-30$34.00K
10-Q · filed 2023-11-14
$176.00K
derived: sum of 2 quarters · filed 2023-11-14
$268.00K
10-Q · filed 2023-11-14
$384.00K
derived: sum of 4 quarters · filed 2024-05-14
2023-06-30$142.00K
10-Q · filed 2023-08-14
$234.00K
10-Q · filed 2023-08-14
$350.00K
derived: sum of 3 quarters · filed 2024-05-14
$385.00K
derived: sum of 4 quarters · filed 2024-05-14
2023-03-31$92.00K
10-Q · filed 2024-05-14
$208.00K
derived: sum of 2 quarters · filed 2024-05-14
$243.00K
derived: sum of 3 quarters · filed 2024-05-14
$276.00K
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31$116.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08
$151.00K
derived: sum of 2 quarters · filed 2024-03-08
$184.00K
derived: sum of 3 quarters · filed 2024-03-08
$223.00K
10-K · filed 2024-03-08
$12.00K
10-K · filed 2023-03-13
2022-09-30$35.00K
10-Q · filed 2023-11-14
$68.00K
derived: sum of 2 quarters · filed 2023-11-14
$107.00K
10-Q · filed 2023-11-14
2022-06-30$33.00K
10-Q · filed 2023-08-14
$72.00K
10-Q · filed 2023-08-14
2022-03-31$39.00K
10-Q · filed 2023-05-11
2021-09-30$27.00K
10-Q · filed 2022-11-14
$238.00K
10-Q · filed 2022-11-14
2020-12-31$93.00K
10-K · filed 2022-05-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Lipocine Inc. (LPCN)United States$0.017B-1.79
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Korsana Biosciences, Inc. (CYCN)United States$0.016B
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
Rocket One Inc. (RKTO)United States$0.019B
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B